By Adria Calatayud

Novartis said its Scemblix drug met its primary goals in a late-stage clinical trial for newly diagnosed patients with chronic myeloid leukemia.

The Swiss pharmaceutical company said Monday that Scemblix showed superior major molecular response compared to approved standard-of-care treatments that known as tyrosine kinase inhibitors--a type of targeted therapy--at week 48 of treatment.

Scemblix also demonstrated a favorable safety and tolerability profile with fewer adverse events and treatment discontinuations relative to the standard of care, Novartis said.

The company said the trial continues and that it will release new data evaluating patients' major molecular response after 96 weeks of treatment, the key secondary goal of the trial, as well as other secondary objectives.

Details will be presented at an upcoming medical conference and included as part of regulatory submissions in 2024, Novartis said.

Write to Adria Calatayud at adria.calatayud@wsj.com

(END) Dow Jones Newswires

January 08, 2024 01:46 ET (06:46 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
Grafico Azioni Novartis (NYSE:NVS)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Novartis
Grafico Azioni Novartis (NYSE:NVS)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Novartis